Alk-Abello AS (CHIX:ALKBC) Debt-to-Asset : 0.04 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ALKBC Alk-Abello AS CHIX:ALKBC
91 GF Score
Price kr221.50
GF Value kr226.44
Valuation Fairly Valued
View Full Analysis

What is Alk-Abello AS Debt-to-Asset?

Alk-Abello AS CHIX:ALKBC 91 Debt-to-Asset is 0.04 as of Jun. 2026. GuruFocus rates CHIX:ALKBC with a GF Score™ of 91/100 and a GF Value™ of kr226.44 (Fairly Valued).

Alk-Abello AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr60 Mil. Alk-Abello AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr362 Mil. Alk-Abello AS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was kr9,725 Mil. Alk-Abello AS's debt to asset for the quarter that ended in Jun. 2026 was 0.04.

Alk-Abello AS  (CHIX:ALKBc) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Alk-Abello AS Debt-to-Asset Related Terms

Alk-Abello AS Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Alk-Abello AS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS Debt-to-Asset Chart

Alk-Abello AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.11 0.11 0.14 0.05

Alk-Abello AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.05 0.04 0.04

CHIX:ALKBC vs VRTX, REGN, RVMD: Debt-to-Asset Comparison

For the Biotechnology subindustry, Alk-Abello AS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alk-Abello AS Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Debt-to-Asset falls into.


CHIX:ALKBC
91GF Score
Alk-Abello AS CHIX:ALKBC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alk-Abello AS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alk-Abello AS's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(63 + 355) / 9057
=0.05

Alk-Abello AS's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(60 + 362) / 9725
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.04 mean?
Alk-Abello AS (CHIX:ALKBC) has a Debt-to-Asset of 0.04 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Alk-Abello AS and its competitors.
Is Alk-Abello AS's Debt-to-Asset too high?
Alk-Abello AS's current Debt-to-Asset is 0.04. Overall, Alk-Abello AS has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Debt-to-Asset compare to VRTX and REGN?
Alk-Abello AS's Debt-to-Asset of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Alk-Abello AS and its competitors. Alk-Abello AS's current Debt-to-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Fairly Valued. The stock's GF Value™ is kr226.44, compared to a current price of kr221.50 — trading 2.2% below its estimated fair value. The current Debt-to-Asset is 0.04. Alk-Abello AS's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Debt-to-Asset is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be undervalued. The current stock price of kr221.50 is trading 2.2% below its estimated GF Value™ of kr226.44. GuruFocus considers Alk-Abello AS to be Fairly Valued.

Key valuation signals for CHIX:ALKBC:

  • Debt-to-Asset: 0.04
  • GF Value™: kr226.44 vs. price of kr221.50 (2.2% below fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
91GF Score

Get the complete analysis for CHIX:ALKBC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr221.50
Price
kr226.44
GF Value